NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: UpSpring PR
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharmalogical, Inc. Announces Official Launch of Fibrosolve - Pharmalogical, Inc. has developed the little pink pill for the treatment and prevention of fibroadenoma: Fibrosolve. Fibrosolve has launched today - PharmalogicalInc.com
Pharmalogical, Inc. Announces Official Launch of Fibrosolve

 

NewswireToday - /newswire/ - New York, NY, United States, 2009/11/16 - Pharmalogical, Inc. has developed the little pink pill for the treatment and prevention of fibroadenoma: Fibrosolve. Fibrosolve has launched today - PharmalogicalInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Liam Scully, President of Pharmalogical, Inc. announced that Fibrosolve, an all-natural supplement for the treatment and prevention of fibroadenomas*, will launch today, Nov. 16. Fibrosolve, "the little pink pill," will have a major impact on breast health and awareness, providing women with a noninvasive, risk-free treatment option for fibroadenomas.

"Fibrosolve is crucially important for breast health," says Mr. Scully. "Until now, women have not had a preventative option for fibroadenoma, or a natural treatment plan. Now women have options beyond simply monitoring the lump or resorting to surgery, giving women a healthy, safe alternative."

Fibroadenomas, which can be detected through regular breast exams, are benign breast tumors made of glandular and fibrous breast tissue. According to the Gale Encyclopedia of Medicine fibroadenomas occur among 10 percent of the female population, as well as 20 percent of African-American women. Fibroadenomas are most common in women ages 15-30, and pregnant women. Fibroadenomas are not cancerous, but the presence of fibroadenomas can increase the risk of a breast cancer diagnosis later in life. Women with multiple or complex fibroadenomas are about twice as likely to be diagnosed with breast cancer than women without fibroadenomas. While there is obviously no safeguard against a breast cancer diagnosis, it is important for women to be aware of all of their options, as well as all the methods to avoid a diagnosis. Fibrosolve is the only way to reduce the risk and appearance of fibroadenomas without an invasive surgical procedure.*

Until now, there has been no preventative treatment for fibroadenoma. The only options for women have been watchful waiting or an invasive, surgical procedure to remove the fibroadenoma. Even beyond the risks of surgery and anasthesia, women with small busts have had to deal with the deformities or irregularities associated with multiple lumpectomies.

Fibrosolve is the only way for women to both reduce the size of existing fibroadenomas and prevent the growth of future ones. It represents a major step forward in the promotion and knowledge of breast health.

Fibrosolve is now available to consumers nationwide on the Pharmalogical, Inc. Website.

About Pharmalogical, Inc.
Pharmalogical, Inc. (Pharmalogicalinc.com) is a Long Island-based wholesaler and distributor of medical products and devices that is committed to providing the best customer service with the highest standard of ethics. The company is a licensed distributer cosmetic products like Botox, Restylane and Surgiderm, in addition to the BiomarC Tissue Marker System, a radiology product. Pharmalogical, Inc. provides its customers with the fairest and most affordable prices by buying wholesale from overseas, and passing on the cost savings directly to the customer.

Pharmalogical, Inc. is located at 1010 Northern Boulevard, Great Neck, NY 11021. For sales, call 888-868-6147, or email sales[.]pharmalogicalinc.com.

* This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: UpSpring PR

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharmalogical, Inc. Announces Official Launch of Fibrosolve

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Madeleine Desmond - UpSpringPR.com 
914-500-3189 madeleine.desmond[.]upspringpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any UpSpring PR securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From UpSpring PR / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)